Skip To Main Content

Explore Toujeo® (insulin glargine 300 Units/mL) data from the pivotal randomised controlled clinical trials

Hypoglycaemia is the most frequent adverse reaction observed in clinical trials conducted with Toujeo®.7 Other common adverse effects are lipohypertrophy and injection site reactions.7

For further information on the safety profile of Toujeo® please consult the Summary of Product Characteristics >

  1. Danne T, Matsuhisa M et al. Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: a meta-analysis of 6-month phase 3 clinical trials. Diabetes Obes Metab 2020;22(10):1880-1885
  2. Ritzel R, Roussel R et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab 2015;17(9):859-867
  3. Ritzel R, Roussel R et al. Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes. Diabetes Obes Metab 2018;20(3):541-548
  4. Battelino T, Bosnyak Z et al. InRange: comparison of the second-generation basal insulin analogues glargine 300 u/ml and degludec 100 u/ml in persons with type 1 diabetes using continuous glucose monitoring-study design. Diabetes Ther 2020;11(4):1017-1027
  5. Battelino T, Danne T et al. Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: the head-to-head randomised controlled InRange trial. Diabetes Obes Metab 2023;25(2):545-555
  6. Rosenstock J, Cheng A et al. More similarities than differences testing insulin glargine 300 units/ml versus insulin degludec 100 units/ml in insulin-naive type 2 diabetes: the randomised head-to-head BRIGHT trial. Diabetes Care 2018;41(10):2147-2154
  7. Toujeo Summary of Product Characteristics

ARR: Absolute Risk Reduction

HR: Hazard Ratio

OR: Odds Ratio

RR: Relative Risk

T1D – Type-1 Diabetes

T2D – Type -2 Diabetes

Diabetes Products

Toujeo® Product Page

Click here for Prescribing Information

 

MAT-IE-2300465 (v1.0)
Date of preparation: July 2024

Lantus® Product Page

Click here for Prescribing Information

 

MAT-IE-2300466 (v1.0)
Date of preparation: May 2024

MAT-IE-2300507 (v1.0)
Date of Preparation: July 2024